First-Line Triplet Combination of Zolbetuximab, mFOLFOX6 and Nivolumab Supports Targeting CLDN18.2 in HER2-negative, Advanced Gastric or GEJ Adenocarcinoma By Ogkologos - March 24, 2026 183 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ILUSTRO study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR American tobacco company Philip Morris International offers £1bn for UK pharma... July 9, 2021 A Favourable Benefit-Risk Profile for Taletrectinib in TKI-Naїve and Crizotinib-Pretreated Patients... July 24, 2024 LGBTQ+ Voices: Listening to Sexual and Gender Minority People Affected by... May 1, 2024 Scientists Discover How Air Pollution May Trigger Lung Cancer in Never-Smokers... September 10, 2022 Load more HOT NEWS Outcome of EMA Assessment on Use of Lutetium (177Lu) in Treatment... The Largest Randomised Study to Date Points to Low Ipsilateral Breast... EMA Adopts a Positive Opinion for Dabrafenib for the Treatment of... Nirogacestat May Offer Hope to People with Desmoid Tumors
